ALT5 Sigma (AIFC) versus Its Competitors Financial Survey

ALT5 Sigma (NASDAQ:AIFC) is one of 345 publicly-traded companies in the “Financial Services” industry, but how does it compare to its rivals? We will compare ALT5 Sigma to related businesses based on the strength of its dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and profitability.

Profitability

This table compares ALT5 Sigma and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-4,021.65%	-51.87%	-48.30%
ALT5 Sigma Competitors	-405.72%	-21.94%	-5.67%

Volatility and Risk

ALT5 Sigma has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500. Comparatively, ALT5 Sigma’s rivals have a beta of 2.21, suggesting that their average stock price is 121% more volatile than the S&P 500.

Earnings and Valuation

This table compares ALT5 Sigma and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
ALT5 Sigma	$24.84 million	-$344.51 million	1.33
ALT5 Sigma Competitors	$6.68 billion	$1.08 billion	10.50

ALT5 Sigma’s rivals have higher revenue and earnings than ALT5 Sigma. ALT5 Sigma is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings for ALT5 Sigma and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1	0	0	0	1.00
ALT5 Sigma Competitors	1894	6809	11510	414	2.51

As a group, “Financial Services” companies have a potential upside of 4.15%. Given ALT5 Sigma’s rivals stronger consensus rating and higher possible upside, analysts plainly believe ALT5 Sigma has less favorable growth aspects than its rivals.

Institutional and Insider Ownership

6.3% of ALT5 Sigma shares are held by institutional investors. Comparatively, 43.0% of shares of all “Financial Services” companies are held by institutional investors. 0.2% of ALT5 Sigma shares are held by company insiders. Comparatively, 21.8% of shares of all “Financial Services” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

ALT5 Sigma rivals beat ALT5 Sigma on 13 of the 13 factors compared.

ALT5 Sigma Company Profile

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.